In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
Dry material: Follow the vial and batch documentation for temperature, moisture, and light protection [13]
Unfortunately, many people are deficient in vitamin B12 as the body cannot produce the nutrient on its own
This includes an Rx order from a 503B FDA compliant compounding facility, NOT a research use only chemical
That creates the conditions tissue needs to actually heal [1]
Oxidation reactions produce modified peptides with altered or absent biological activity